Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shelter Pharma Ltd has submitted its 18th Annual Report for FY 2024-25 to BSE, along with the notice for its 18th Annual General Meeting scheduled on September 30, 2025. Revenue from operations grew 26.58% YoY to Rs. 5,066.02 lakhs, EBITDA rose to Rs. 1,007.33 lakhs, profit before tax stood at Rs. 967.70 lakhs, and profit after tax was Rs. 723.74 lakhs, translating to an EPS of Rs. 6.26 per share. The company has recommended a dividend of Rs. 0.35 per share (3.5%) for the year. The AGM notice includes agenda items for adopting financial statements, re-appointment of the Managing Director, appointment of new statutory auditors (M/s Alvi & Associates, replacing the resigned Mendajiwala & Co), and appointment of secretarial auditors. Shelter Pharma is a Gujarat-based herbal/Ayurvedic pharmaceutical company with operations in human healthcare, veterinary products, and nutraceuticals, exporting to 10 countries.
Strong double-digit revenue and profit growth, combined with a dividend declaration, signals healthy business momentum and shareholder returns. The change of statutory auditors mid-term (resignation effective August 20, 2025) is a governance point worth monitoring, though the company has appointed a replacement. Overall, the filing reflects positive financial performance with no negative triggers.